GLIS3 Gene Diabetes Mellitus, Neonatal – Genetic Test in UAE

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing.
Premium Home Collection: Hospital‑grade cold‑chain phlebotomy (8 AM–11 PM), VIP mobile service.
Post‑Test Clinical Guidance: Telephonic interpretation by DHA‑licensed genetics specialist.
Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This next‑generation sequencing (NGS) test analyzes the entire GLIS3 gene to detect pathogenic variants responsible for neonatal diabetes mellitus—a rare monogenic form presenting in the first six months of life. Results empower precise insulin adjustment, risk stratification for family members, and informed reproductive planning.

Why Our Test Outperforms Standard Alternatives

Feature	Our NGS Test	Closest Alternative (Single‑Gene Sequencing)
Diagnostic Sensitivity	99.9% (full gene coverage, intronic regions included)	~85% (selective exons)
Methodology	NGS with copy‑number variant analysis	Sanger sequencing of limited hotspots
Turnaround Time	3–4 Weeks	6–8 Weeks
UAE Accreditation	ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)	Often none

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics, I interpret GLIS3 results in the context of neonatal diabetes. A positive test confirms the diagnosis and may guide therapy switching from insulin to sulfonylureas. However, negative results do not exclude other genetic causes, and all infants require ongoing glucose monitoring. This result is a guide, not an endpoint; comprehensive pediatric endocrinology follow‑up is essential.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Medication Advisory

Do not discontinue prescribed insulin or any medication without consulting the treating physician. Abrupt changes can trigger life‑threatening ketoacidosis.

Exclusion Criteria & Emergency Red Flags

Patients unable to provide the required sample (blood or FTA card) due to severe anemia or coagulopathy unmanaged.
Acute febrile illness requiring immediate hospitalization.
Seek Emergency Care if the patient develops: rapid deep breathing, persistent vomiting, altered consciousness, signs of dehydration (sunken eyes, dry mouth), or extreme lethargy.

Patient FAQ & Clinical Guidance

1. What does the GLIS3 gene test reveal, and when is it indicated?

The GLIS3 NGS test detects pathogenic mutations in the GLIS3 gene causing permanent neonatal diabetes mellitus, thereby confirming the molecular diagnosis in infants with hyperglycemia before six months of age.

2. How is the sample collected, and what are the home collection logistics?

A trained phlebotomist collects 2‑3 mL of whole blood or a finger‑prick FTA card at your home under cold‑chain protocol, fully compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection service is available daily from 8 AM to 11 PM.

3. Will insurance cover this genetic test, and how do I confirm?

Most UAE insurers reimburse neonatal diabetes genetic testing when medically indicated; send your policy details via WhatsApp to +971 54 548 8731 for direct billing verification before the appointment.

UAE Regulatory & Data Privacy Adherence

All patient data is processed in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety is governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory operates under DHA Facility License No. 1143.

Clinical & Logistical Metadata

Test Name	GLIS3 Gene Diabetes Mellitus, Neonatal – Genetic Test
Price (AED)	2,800
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole blood (2–3 mL) or FTA card; VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM)
Methodology Used	Next‑Generation Sequencing (NGS) with copy‑number variant analysis
ICD-10-CM Code	P70.2
LOINC Code	21619-7
DHA Facility License & Laboratory Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE